CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0676 (clinicaltrials.gov NCT No: NCT00530907)
Title:Phase I study of Valproic Acid Given in Combination with Bevacizumab in Patients with Advanced Cancer to Determine Safety and Tolerability
Principal Investigator:Jennifer J. Wheler
Treatment Agent:Bevacizumab; Valproic Acid
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of
bevacizumab in combination with valproic acid that can be given to patients
with advanced cancer that has not responded to standard treatment or where
there is no standard treatment for the disease. The safety of this drug
combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Phase I Studies
Phase of Study:Phase I
Treatment Agents:Bevacizumab
Valproic Acid
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Patients will be required to return to MDACC weekly for cycle 1 and 2.
Patients will be required to return every other week for cycle 3-4 and monthly
thereafter.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jennifer J. Wheler
Dept:Phase I Program
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults